CML中关于停用TKI及无治疗生存的研究进展  

Progress in research on discontinuation of TKI and no-treatment survival in CML

作　　者：高九青[1] 吴丹阳 杨威[2] GAO Jiu-qing;WU Dan-yang;YANG Wei(General Hospital of Fuxin Mining Group, Fuxin 123000, China;Shengjing Hospital of China Medical University,Shenyang 110022 ,China)

机构地区：[1]阜新矿业集团总医院,辽宁阜新123000 [2]中国医科大学属盛京医院,沈阳110022

出　　处：《实用药物与临床》2018年第3期333-338,共6页Practical Pharmacy and Clinical Remedies

摘　　要：慢性粒细胞白血病(Chronic myeloid leukemia,CML)的治疗以应用酪氨酸激酶抑制剂(Tyrosine kinase inhibitor,TKI)及造血干细胞移植为主,TKI的应用极大地改善了CML患者的预后,但其不间断的终身治疗,不仅加重了患者的经济负担,而且影响患者的生存质量。本文通过CML中关于停用TKI及无治疗生存的研究进展,分析现阶段关于该论点的相关问题。The treatment for chronic myeloid leukemia（CML） focuses on the use of tyrosine kinase inhibitor（TKI） and transplantation of hematopoietic stem cell.The TKI greatly improves the prognosis of patients with CML,but its uninterrupted life-long treatment not only increases the patient’s economic burden,but also affects the quality of patients’ life.In this paper,through the progress of the research on the discontinuation of TKI and the survival without treatment,the relevant issues at this stage are analyzed.

关 键 词：CML TKI 研究进展 

分 类 号：R733.72[医药卫生—肿瘤]